Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma

Signal Transduct Target Ther. 2021 Jul 28;6(1):275. doi: 10.1038/s41392-021-00609-0.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Glioblastoma* / genetics
  • Glioblastoma* / immunology
  • Glioblastoma* / therapy
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology*
  • Mice
  • Neoplasm Proteins / deficiency*
  • Neoplasm Proteins / immunology
  • Oncolytic Virotherapy*
  • Oncolytic Viruses / immunology*
  • PTEN Phosphohydrolase / deficiency*
  • PTEN Phosphohydrolase / immunology
  • Phosphatidylinositol 3-Kinases* / genetics
  • Phosphatidylinositol 3-Kinases* / immunology
  • Tumor Microenvironment* / genetics
  • Tumor Microenvironment* / immunology

Substances

  • Immune Checkpoint Inhibitors
  • Neoplasm Proteins
  • PTEN Phosphohydrolase
  • PTEN protein, human